RecruitingPhase 2NCT06092034
A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease
Studying Danon disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Rocket Pharmaceuticals Inc.
- Principal Investigator
- Joseph Rossano, MDChildren's Hospital of Philadelphia
- Intervention
- RP-A501(genetic)
- Enrollment
- 14 enrolled
- Eligibility
- 8 years · MALE
- Timeline
- 2023 – 2032
Study locations (6)
- University of California, San Diego, La Jolla, California, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- German Heart Center Munich, Munich, Germany
- Meyer Childrens Hospital, Florence, Italy
- Great Ormund Street Hospital & UCL Institute of Cardiovascular Science, London, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06092034 on ClinicalTrials.govOther trials for Danon disease
Additional recruiting or active studies for the same condition.